<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359644</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-040</org_study_id>
    <nct_id>NCT01359644</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care</brief_title>
  <official_title>Parallel, Open-Label, Randomized Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PSI-7977 in Combination With BMS-790052 With or Without Ribavirin in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotypes 1, 2, or 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmasset</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether therapy with the combination of PSI-7977
      and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C
      virus (HCV) infection when given for 12 or 24 weeks as measured by sustained virologic
      response with undetectable HCV RNA 12 weeks post treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)</measure>
    <time_frame>Follow-up Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected (ie, HCV RNA &lt;25 IU/mL) at follow-up Week 12. DCV=daclatasvir, SOF=sofosbuvir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)</measure>
    <time_frame>Follow-up Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR24 was defined as participant's hepatitis C virus RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 24. DCV=daclatasvir, SOF=sofosbuvir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Breakthrough During the Treatment Period</measure>
    <time_frame>First dose of study drug (Day 1) up to end of treatment period (up to 12 or 24 weeks, depending on treatment group)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral breakthrough is defined as any confirmed increase in viral load ≥1 log from nadir or any confirmed hepatitis C virus RNA levels ≥25 IU/mL on or after Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Viral Relapse During Follow-up Period</measure>
    <time_frame>Day 1 of follow-up period (Week 13 or 25, depending on treatment group) to end of follow-up period (up to 48 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral relapse during follow-up is defined as any confirmed quantifiable hepatitis C virus (HCV) RNA ≥25 IU/mL with HCV RNA levels less than the lower limit of quantitation, target detected or target not detected, ie, HCV RNA &lt;25 IU/mL at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24</measure>
    <time_frame>Baseline, Follow-up week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in log10 HCV RNA at scheduled sampling time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy</measure>
    <time_frame>First dose of study drug (Day 1) up to the start of rescue therapy (12 or 24 weeks, depending on treatment group)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Based on the severity, AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period</measure>
    <time_frame>AEs: From Day 1 of follow-up period (Week 13 or 25) up to study discharge (up to 72 weeks). SAEs: From Day 1 of follow-up period (Week 13 or 25) up to 30 days after study discharge (up to 74 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. Based on the severity, AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Very severe</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment A: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1a or 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 2 or 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1a or 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 2 or 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1a or 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F: PSI-7977 + Daclatasvir+ Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 2 or 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment G: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis C virus genotype 1, treatment-naive patients
Genotype 1a or 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment H: PSI-7977 + BMS-790052 + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis C virus genotype 1, treatment-naive patients
Genotype 1a or 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment I: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who experienced telaprevir/boceprevir treatment failure
Genotype 1a or 1b</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment J: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who experienced telaprevir/boceprevir treatment failure
Genotype 1a or 1b</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSI-7977</intervention_name>
    <description>Tablets, oral, 400 mg, once daily</description>
    <arm_group_label>Treatment A: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment B: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment C: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment D: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment E: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <arm_group_label>Treatment F: PSI-7977 + Daclatasvir+ Ribavirin</arm_group_label>
    <arm_group_label>Treatment G: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment H: PSI-7977 + BMS-790052 + Ribavirin</arm_group_label>
    <arm_group_label>Treatment I: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment J: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Tablets, oral, 60 mg, once daily</description>
    <arm_group_label>Treatment A: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment B: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment C: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment D: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment E: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <arm_group_label>Treatment F: PSI-7977 + Daclatasvir+ Ribavirin</arm_group_label>
    <arm_group_label>Treatment G: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment H: PSI-7977 + BMS-790052 + Ribavirin</arm_group_label>
    <arm_group_label>Treatment I: PSI-7977 + Daclatasvir</arm_group_label>
    <arm_group_label>Treatment J: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablets, oral, 200 mg</description>
    <arm_group_label>Treatment E: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <arm_group_label>Treatment F: PSI-7977 + Daclatasvir+ Ribavirin</arm_group_label>
    <arm_group_label>Treatment H: PSI-7977 + BMS-790052 + Ribavirin</arm_group_label>
    <arm_group_label>Treatment J: PSI-7977 + Daclatasvir + Ribavirin</arm_group_label>
    <other_name>Copegus ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages 18 to 70 years.

          -  Participants infected with hepatitis C virus (HCV) genotype 1, 2, or 3, with no
             previous exposure to an interferon formulation (ie, interferon-alpha, pegylated
             interferon-alpha) ribavirin, or other HCV-specific direct-acting antiviral (including
             daclatasvir and PSI-7977).

          -  Patients should have chronic hepatitis C genotype 1a, 1b, 2, or 3 as documented by:
             positive test results for anti-HCV antibody; HCV RNA; or a HCV genotype at least 6
             months prior to screening, and HCV RNA and anti-HCV antibody at the time of
             screening.

        Exclusion Criteria:

          -  Evidence of a medical condition associate with chronic liver disease other than HCV.

          -  History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
             with diuretics or paracentesis.

          -  History of hemophilia.

          -  History of torsade de pointes.

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to enrollment.

          -  History of gastrointestinal disease or surgical procedure (except cholecystectomy).

          -  History of clinically significant cardiac disease.

          -  Blood transfusion within 4 weeks prior to study drug administration.

          -  Poor venous access.

          -  Any other medical, psychiatric, and/or social reason which, in the opinion of the
             Investigator, would make the candidate inappropriate for participation in this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Liver Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research And Education, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Denver &amp; Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Florida Hepatology</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Va Medical Center 3c Sub-J</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 23, 2015</lastchanged_date>
  <firstreceived_date>May 23, 2011</firstreceived_date>
  <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
